Gene
CSF1R
CSF1R is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (21), Actionable biomarkers (1), Trial mentions (208), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CSF1R. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 18 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 10 of 8,738 | 0.11% | not measured | |
| 2025 | 13 of 8,875 | 0.15% | not measured | |
| 2024 | 17 of 8,597 | 0.20% | not measured | |
| 2023 | 15 of 8,275 | 0.18% | 24 of 11,460 | 0.21% |
| 2022 | 11 of 8,285 | 0.13% | 38 of 13,598 | 0.28% |
| 2021 | 20 of 8,692 | 0.23% | 48 of 15,045 | 0.32% |
| 2020 | 10 of 7,640 | 0.13% | 52 of 14,459 | 0.36% |
| 2019 | 11 of 7,300 | 0.15% | 38 of 12,159 | 0.31% |
| 2018 | 11 of 6,927 | 0.16% | 21 of 11,854 | 0.18% |
| 2017 | 13 of 6,558 | 0.20% | 22 of 11,595 | 0.19% |
Showing 10 of 37 years.
Assay-provider ledger (21)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent | Reagent supplier | Analytical validation | 2 | November 19, 2014 |
| AB Applied Biosystems | Reagent supplier | Clinical validationAnalytical validation | 3 | November 19, 2014 |
| Invitrogen | Reagent supplier | Analytical validation | 1 | November 19, 2014 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 2 | November 19, 2014 |
| Sigma Aldrich | Reagent supplier | Analytical validation | 2 | November 19, 2014 |
Showing 5 of 21 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CSF1R (Y571D) | Imatinib | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
Trial mentions (208)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07447102 | Trial eligibility (AACT) |
| NCT00392041 | Trial eligibility (AACT) |
| NCT07686952 | Trial eligibility (AACT) |
| NCT02371369 | Trial eligibility (AACT) |
| NCT05020743 | Trial eligibility (AACT) |
Showing 5 of 208 trial mentions.
Target-disease associations (711)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Acute hepatic failure | phenotype | Expression Atlas |
| Adult-onset autosomal dominant leukodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 711 associations.
Vendor sourcing (615)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | IA different missense change at the same codon (p.Glu633Lys) has been reported to be associated with CSF1R related disorder (ClinVar ID: VCV000029811, PM5_M)... | View ClinVar record SCV002058352.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV007332858.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | to participate in this study: * Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may b... | View trial NCT04070768 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | FMS | View trial NCT04070768 |
| AbbVie Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016). * Should have failed at least 1 lin... | View trial NCT03625505 |
Showing 5 of 615 sourcing records.
Trial-cited literature (386)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Current Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature. | JB & JS open access | 2026 | 2 |
| Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France. | Blood advances | 2025 | 13 |
| Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial. | Journal for immunotherapy of cancer | 2025 | 8 |
| Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. | Breast cancer research and treatment | 2025 | 4 |
| A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor. | Oncology and therapy | 2025 | 3 |
Showing 5 of 386 papers.
Protein variant mentions (19)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C972W | 1 | 2015 | PMID 25741868 |
| p.D871E | 1 | 2015 | PMID 25741868 |
| p.E200X | 1 | 2022 | PMID 36510622 |
| p.E847D | 1 | 2015 | PMID 25741868 |
| p.G589R | 1 | 2015 | PMID 25741868 |
Showing 5 of 19 variants.
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Imatinib | Chemical | negative_correlate |
Treatment updates on tenosynovial giant cell tumor. | 2022 |
| Imatinib | Chemical | negative_correlate |
The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT. | 2020 |
| DASATINIB | Chemical | associate |
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. | 2014 |
| SUNITINIB | Chemical | negative_correlate |
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 |
| Flutamide | Chemical | negative_correlate |
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence. | 2014 |
Showing 5 of 61 relation assertions.
Organizations publishing (372)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 25 | 2013 to 2024 |
| Dana-Farber Cancer Institute | Other | 19 | 2002 to 2025 |
| Mayo Clinic | Hospital | 16 | 2013 to 2025 |
| Mass General Brigham | Hospital | 15 | 2015 to 2023 |
| Centre Léon Bérard | Nonprofit | 13 | 2014 to 2025 |
Showing 5 of 372 organizations.
Where CSF1R appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
609 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.